Literature DB >> 24998288

Novel treatment strategies for brain tumors and metastases.

Salma E El-Habashy1, Alaa M Nazief, Chris E Adkins, Ming Ming Wen, Amal H El-Kamel, Ahmed M Hamdan, Amira S Hanafy, Tori O Terrell, Afroz S Mohammad, Paul R Lockman, Mohamed Ismail Nounou.   

Abstract

This review summarizes patent applications in the past 5 years for the management of brain tumors and metastases. Most of the recent patents discuss one of the following strategies: the development of new drug entities that specifically target the brain cells, the blood-brain barrier and the tumor cells, tailor-designing a novel carrier system that is able to perform multitasks and multifunction as a drug carrier, targeting vehicle and even as a diagnostic tool, direct conjugation of a US FDA approved drug with a targeting moiety, diagnostic moiety or PK modifying moiety, or the use of innovative nontraditional approaches such as genetic engineering, stem cells and vaccinations. Until now, there has been no optimal strategy to deliver therapeutic agents to the CNS for the treatment of brain tumors and metastases. Intensive research efforts are actively ongoing to take brain tumor targeting, and novel and targeted CNS delivery systems to potential clinical application.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24998288      PMCID: PMC4465202          DOI: 10.4155/ppa.14.19

Source DB:  PubMed          Journal:  Pharm Pat Anal        ISSN: 2046-8954


  93 in total

1.  Cyclic RGD-polyethylene glycol-polyethylenimine for intracranial glioblastoma-targeted gene delivery.

Authors:  Changyou Zhan; Qinggang Meng; Qinghua Li; Linglin Feng; Jianhua Zhu; Weiyue Lu
Journal:  Chem Asian J       Date:  2011-11-09

Review 2.  Structural and functional aspects of the blood-brain barrier.

Authors:  David J Begley; Milton W Brightman
Journal:  Prog Drug Res       Date:  2003

3.  Drug discovery for CNS disorders: from bench to bedside.

Authors:  Aleksey G Kazantsev; Tiago Fleming Outeiro
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-12       Impact factor: 4.388

Review 4.  Blood-brain barrier delivery.

Authors:  William M Pardridge
Journal:  Drug Discov Today       Date:  2006-11-13       Impact factor: 7.851

Review 5.  Drug metabolizing enzymes in the brain and cerebral microvessels.

Authors:  A Minn; J F Ghersi-Egea; R Perrin; B Leininger; G Siest
Journal:  Brain Res Brain Res Rev       Date:  1991 Jan-Apr

Review 6.  Polymeric nanoparticles for drug delivery to the central nervous system.

Authors:  Toral Patel; Jiangbing Zhou; Joseph M Piepmeier; W Mark Saltzman
Journal:  Adv Drug Deliv Rev       Date:  2011-12-20       Impact factor: 15.470

7.  Central nervous system metastasis from breast carcinoma. Autopsy study.

Authors:  Y Tsukada; A Fouad; J W Pickren; W W Lane
Journal:  Cancer       Date:  1983-12-15       Impact factor: 6.860

8.  AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.

Authors:  O L Chinot; T de La Motte Rouge; N Moore; A Zeaiter; A Das; H Phillips; Z Modrusan; T Cloughesy
Journal:  Adv Ther       Date:  2011-03-14       Impact factor: 3.845

9.  Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse.

Authors:  Ruben J Boado; Yun Zhang; Yuntao Wang; William M Pardridge
Journal:  Biotechnol Bioeng       Date:  2009-03-01       Impact factor: 4.530

Review 10.  Diagnosis and management of central nervous system metastases from breast cancer.

Authors:  Eric L Chang; Simon Lo
Journal:  Oncologist       Date:  2003
View more
  7 in total

Review 1.  Modern stem cell therapy: approach to disease.

Authors:  Mateja Zemljic; Bozena Pejkovic; Ivan Krajnc; Lidija Kocbek
Journal:  Wien Klin Wochenschr       Date:  2015-12-10       Impact factor: 1.704

2.  Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer.

Authors:  Afroz S Mohammad; Jessica I Griffith; Chris E Adkins; Neal Shah; Emily Sechrest; Emma L Dolan; Tori B Terrell-Hall; Bart S Hendriks; Helen Lee; Paul R Lockman
Journal:  Pharm Res       Date:  2018-01-09       Impact factor: 4.200

3.  M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrier.

Authors:  Andreas Machl; Erik W Wilker; Hui Tian; Xiaohong Liu; Patricia Schroeder; Anderson Clark; Bayard R Huck
Journal:  Am J Cancer Res       Date:  2016-03-15       Impact factor: 6.166

4.  Permeability changes and effect of chemotherapy in brain adjacent to tumor in an experimental model of metastatic brain tumor from breast cancer.

Authors:  Afroz S Mohammad; Chris E Adkins; Neal Shah; Rawaa Aljammal; Jessica I G Griffith; Rachel M Tallman; Katherine L Jarrell; Paul R Lockman
Journal:  BMC Cancer       Date:  2018-12-07       Impact factor: 4.430

5.  Dynamic urinary proteomic analysis in a Walker 256 intracerebral tumor model.

Authors:  Linpei Zhang; Yuqiu Li; Wenshu Meng; Yanying Ni; Youhe Gao
Journal:  Cancer Med       Date:  2019-05-15       Impact factor: 4.452

6.  Synthesis, Cytotoxic Activity Evaluation and Quantitative Structure-Activity Analysis of Substituted 5,8-Dihydroxy-1,4-Naphthoquinones and their O- and S-Glycoside Derivatives Tested Against Neuro-2a Cancer Cells.

Authors:  Sergey Polonik; Galina Likhatskaya; Yuri Sabutski; Dmitry Pelageev; Vladimir Denisenko; Evgeny Pislyagin; Ekaterina Chingizova; Ekaterina Menchinskaya; Dmitry Aminin
Journal:  Mar Drugs       Date:  2020-11-29       Impact factor: 5.118

7.  Patents and Innovation Among Neurosurgeons from the American Association of Neurological Surgeons.

Authors:  Rebecca B Baron; Remi A Kessler; Ansh Bhammar; Nicholas Boulis; John R Adler; Karan Kohli; Constantinos Hadjipanayis
Journal:  Cureus       Date:  2020-02-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.